Detalhe da pesquisa
1.
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
N Engl J Med
; 378(4): 354-369, 2018 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29365309
2.
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study.
Clin Infect Dis
; 67(7): 1010-1017, 2018 09 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29566246
3.
Multiple Simultaneous Gastrointestinal Parasitic Infections in a Patient with Human Immunodeficiency Virus.
P R Health Sci J
; 35(2): 97-9, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27232872
4.
Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
HIV Clin Trials
; 12(5): 255-67, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-22180523
5.
Tetanus is still present in the 21st century: case report and review of literature.
Bol Asoc Med P R
; 103(2): 41-7, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-22111470
6.
Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2.
Open Forum Infect Dis
; 4(3): ofx154, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28948180
7.
Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study.
AIDS Res Hum Retroviruses
; 29(2): 256-65, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22730929